Drugs / Depemokimab
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Exdensur | — | 2026-02-12 | europa.eu ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05602025 | Dec 2022 → Oct 2023 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT05140200 | Dec 2021 → Dec 2022 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03287310 | Oct 2017 → Jul 2019 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT07671001 | Jun 2026 → Mar 2029 expected | asthma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07456033 | Mar 2026 → Jul 2030 expected | asthma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07177339 | Oct 2025 → Nov 2029 expected | chronic obstructive pulmonary disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06961214 | Jun 2025 → Aug 2029 expected | chronic obstructive pulmonary disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06959095 | Jun 2025 → Aug 2029 expected | chronic obstructive pulmonary disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06979323 | Jul 2024 → Jan 2028 expected | asthma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05334368 | Sep 2022 → Dec 2028 expected | hypereosinophilic syndrome | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT05263934 | Jul 2022 → Sep 2026 expected | eosinophilic granulomatosis with polyangiitis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05274750 | Apr 2022 → Jul 2024 | nasal cavity polyp | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT05281523 | Apr 2022 → Jul 2024 | nasal cavity polyp | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT05243680 | Mar 2022 → May 2025 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04719832 | Mar 2021 → Nov 2023 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04718103 | Feb 2021 → Apr 2024 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT04718389 | Jan 2021 → Sep 2025 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07701967 | Jul 2026 → Jul 2027 expected | nasal cavity polyp | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depemokimab | “GSK3511294 (Depemokimab) 100 mg SC along with the placebo and SOC will be administered.” NCT04718389 ↗15“GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.” NCT05243680 ↗ |
| Known as | AQ-82742999 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650469 ↗ |
| Known as | GSK3511294 | “Depemokimab (GSK3511294) was administered using a pre- filled syringe.” NCT05274750 ↗6“Depemokimab (GSK3511294) was administered using a pre-filled syringe.” NCT05281523 ↗ “GSK3511294 (Depemokimab)” NCT04719832 ↗ |
| Action | Inhibit | “known to block binding of IL-5 to the IL-5 receptor complex” NCT03287310 ↗ |
| Modality | Monoclonal antibody | “GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb)” PMID 34292606 ↗ Aug 2021 |
| Route | Subcutaneous | “GSK3511294 will be administered by SC injection.” NCT03287310 ↗ |
| Target | IL5 | “GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5” NCT03287310 ↗ |